BeiGene, Ltd. (ONC)vsEntrada Therapeutics Inc (TRDA)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
TRDA
Entrada Therapeutics Inc
$12.05
+5.06%
HEALTHCARE · Cap: $439.89M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 20918% more annual revenue ($5.34B vs $25.42M). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
TRDA
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for TRDA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : TRDA
The strongest argument for TRDA centers on Price/Book, Debt/Equity.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : TRDA
The primary concerns for TRDA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while TRDA is a value play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 28/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Entrada Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Entrada Therapeutics Inc. (TRDA) is a pioneering biotechnology firm committed to developing transformative therapies for severe diseases with considerable unmet medical needs. Leveraging its proprietary Therapeutics for RNA Delivery (TRADA) platform, the company targets RNA and protein dysfunctions associated with debilitating conditions such as muscular dystrophies and genetic disorders. With a robust clinical pipeline and an emphasis on scientific rigor, Entrada is strategically positioned to advance therapeutic solutions that seek to enhance patient outcomes, supported by a seasoned leadership team focused on innovation in the biopharmaceutical landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?